Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

AIC649 Positive Phase 1 Hepatitis B


AiCuris Reports Positive Phase 1 Clinical Trial Results with Immunomodulator AIC649 in Patients with Chronic Hepatitis B

  • Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
  • The trial provides evidence that AIC649 stimulates the immune system of chronic hepatitis B patients
  • Further trials to study the potential of AIC649 to induce a functional cure in chronic hepatitis B virus (HBV)-infection is warranted





 Read more ...

Deutscher Zukunftspreis 2018

AiCuris-Team nominated for
Deutscher Zukunftspreis 2018
the German President's Award for
Innovation in Science and Technology

Prof. Dr. Helga Rübsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH are one of three teams nominated for the German President's Award for Innovation in Science and Technology 2018 

  • AiCuris team nominated for their project, "Protection in the Absence of the Immune System - a Life-Saving Innovation against Dangerous Viruses"
  • Together, both scientists developed the world's first and only drug to prevent infections with a common virus in bone marrow transplant patients, generating a paradigm shift in this field of transplantation medicine

 Read more ...

Job Opportunities

Join AiCuris and its quest for novel Anti-Infectives

We offer an exciting and challenging working enviroment in an innovative company with a world-class  R&D Portfolio.





Read more ...